Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Feb;64(1):e72-e75.
doi: 10.1111/ajd.13943. Epub 2022 Nov 1.

Disseminated superficial actinic porokeratosis following hydroxyurea treatment: A case report

Maurizio Romagnuolo  1   2 , Davide Riva  1   2 , Silvia Alberti Violetti  1   2 , Alessandra Di Benedetto  1 , Francesco Barberi  1   2 , Chiara Moltrasio  1   3
Affiliations
Free article
Case Reports

Disseminated superficial actinic porokeratosis following hydroxyurea treatment: A case report

Maurizio Romagnuolo et al. Australas J Dermatol. 2023 Feb.
Free article

Abstract

Porokeratosis encompass a group of acquired and familial, preneoplastic, keratinization disorders, clinically characterized by atrophic macules or patches with a peripheral keratotic rim, the cornoid lamella. Genetic background is recognized as crucial in its pathophysiology, while immunosuppression and ultraviolet radiation represent triggering factors. We report the case of a woman who developed disseminate superficial actinic porokeratosis following the intake of hydroxyurea for a polycythaemia vera. Clinical, dermoscopic and histopathology data are showed, and the role of drug as a second-hit mutation trigger is discussed.

Keywords: Porokeratosis; adverse effect; genetic analysis; hydroxyurea; squamous cells neoplasm mevalonate kinase deficiency.

PubMed Disclaimer

References

REFERENCES

    1. Lu JD, Mufti A, Sachdeva M, Rahat S, Lansang RP, Yeung J. Drugs associated with development of porokeratosis: a systematic review. Dermatol Ther. 2021;34(1):e14560. https://doi.org/10.1111/dth.14560
    1. Zhang SQ, Jiang T, Li M, Zhang X, Ren YQ, Wei SC, et al. Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis. Nat Genet. 2012;44(10):1156-60. https://doi.org/10.1038/ng.2409
    1. Tricarico PM, Crovella S, Celsi F. Mevalonate pathway blockade, mitochondrial dysfunction and autophagy: a possible link. Int J Mol Sci. 2015;16(7):16067-84. https://doi.org/10.3390/ijms160716067
    1. Kubo A, Sasaki T, Suzuki H, Shiohama A, Aoki S, Sato S, et al. Clonal expansion of second-hit cells with somatic recombinations or C>T transitions form porokeratosis in MVD or MVK mutant heterozygotes. J Invest Dermatol. 2019;139(12):2458-2466.e9. https://doi.org/10.1016/j.jid.2019.05.020
    1. Atzmony L, Choate KA. Second-hit somatic mutations in mevalonate pathway genes underlie porokeratosis. J Invest Dermatol. 2019;139(12):2409-11. https://doi.org/10.1016/j.jid.2019.07.723

Publication types